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Al~tract--A T-cell acute lymphoblastic leukemia (T-ALL) patient (female, age 8) was monitored some 
500 days, during which period she had two relapses of the disease. Remission induction by chemotherapy 
was applied three times, starting days 0 (diagnosis), 198 (first relapse) and 365 (second relapse). The first 
two remission induction therapies were successful and therefore were followed by continuous maintenance 
therapy. The second relapse did not respond sufficiently to chemotherapy and the patient died. 
At diagnosis and during follow-up immunological marker was performed on peripheral blood (PB) and 
bone marrow (BM) samples. Double immunofluorescence (IF) staining for a T-cell marker and terminal 
deoxynucleotidyl transferase (TdT) was used as well. This IF assay is a sensitive and specific technique 
for recognizing low numbers of T-ALL cells (one T-ALL cell among 10,000 normal cells). The analyses 
of the PB and BM samples resulted in datapoints of T-ALL cells per mm 3 vs time. The PB and BM plots 
showed similar patterns. The remission periods were characterized bya decline and subsequent regrowth 
of the T-ALL population. 
Based on preclinical studies in a rat model for acute myelocytic leukemia, a mathematical analysis was 
performed. Log-linear egression of the PB datapoints showed that the population doubling time during 
regrowth to relapse was approximately constant (6.5 days, influence of the maintenance therapy included). 
The population half-time during remission induction therapy amounted to 2.8 days. Population dynamics 
were modeled with an exponential growth curve, therapy influence with an exponential decay of the 
therapy level as an approximation of the series of instantaneous "log cell kills" caused by the discrete 
events in the therapy protocol. Curve fitting (standard least squares fitting routine) yielded values for the 
parameters in the drug influence function for each remission induction therapy. The development of
therapy resistance was obvious; equal treatment schedules resulted sequentially in an effective log cell kill 
of 6, 4 and 1. Area under the therapy level curve, as a measure of therapy efficiency, dropped from 229.34 
to 183.61 to 115.27. 
These results indicate that mathematical nalysis of data obtained by a sensitive method for the 
detection of low numbers of malignant cells yields valuable information about the growth characteristics 
of the malignant population, as well as about its therapy sensitivity and the development of therapy 
resistance. 
INTRODUCTION 
The average adult leukemia patient will carry at time of diagnosis a tumor load of some 1012 ceils 
(1 kg). With modern (remission induction) chemotherapy most patients (children 95%, adults 80%, 
Smith et al. [1]) will soon enter an apparent disease-free state (complete remission), i.e. the 
symptoms disappear and in standard tests no leukemic cells can be found anymore. However, that 
the number of malignant cells has disappeared below the clinical level of detection does not mean 
that all clonogenic leukemic cells have been eradicated. This is revealed by the fact that in many 
patients (children 30-40%, adults 70-80%) the disease will return sooner or later (relapse), due 
to regrowth of surviving cells. The clinical detection level is at present about 1%, i.e. the occurrence 
of less than one malignant cell in 100 normal ceils will go unnoticed [2]. In other words, an 
apparently healthy person having 1 kg of marrow may carry an undetectable tumor burden 
(minimal residual disease) of some 0.01 kg, corresponding with 101° leukemic cells. The clinician's 
problem is how to anticipate an imminent relapse and how to tune his (maintenance) chemotherapy 
schedule to prevent or delay it, bearing in mind that patients should be spared the unnecessary 
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toxicity which is inherent o intensive chemotherapy. So, in fact this constitutes an optimization 
problem. 
Therefore, it is most important o gather information on the time-history of the malignant 
population during and after treatment. Before treatment optimization can be dealt with it must 
be known how the malignant population develops, how it reacts--in terms of surviving cell 
numbers--to the drugs administered, and how it will regrow after the chemotherapy. 
In the present study datapoints were gathered by means of immunological marker analysis [3] 
revealing at certain time instants the size of the population of malignant cells in a case of T-cell 
acute lymphoblastic leukemia (T-ALL). The time-history of this population will be regarded as the 
output of a dynamic system which responds to an input signal consisting of the clinically applied 
chemotherapy schedule. The relation between in- and output, as well as the unperturbed output 
behaviour, must be identified. In the first instance, (partially) making use of already accumulated 
knowledge, it is tried to describe the evolution of the population in mathematical terms, in such 
way that the observed atapoints can be explained. 
MATERIALS AND METHODS 
Case report 
After diagnosis an 8-year old girl suffering from T-ALL was monitored uring a period of about 
500 days. During this follow-up period the patient had two relapses of the disease. High intensity 
chemotherapy to obtain remission induction was applied three times, ~tarting on days 0 (diagnosis), 
198 (first relapse) and 365 (second relapse). Such remission induction therapy (RIT) was given 
during 3 weeks, always employing a same multi-drug combination according to a standard 
remission induction protocol. The first two remission induction therapies were successful and were 
therefore followed by a constant low intensity continuous maintenance therapy (CMT) schedule 
consisting of 6-mercaptopurine/methotrexate and, during the first remission, of two additional 
cycles of prednisone treatment, starting on days 121 and 177. The second relapse did not respond 
sufficiently to chemotherapy and the patient died. 
Detection of T-ALL cells by immunological marker analysis 
The malignant cells in nearly all T-ALL express the nuclear enzyme terminal deoxynucleotidyl 
transferase (TdT) and T-cell markers uch as the CD5 antigen on the membrane. Normally, cells 
with the CD5÷/TdT ÷ phenotype are found in the thymus only [4]. The presence of these cells on 
locations outside the thymus is therefore indicative of the presence of T-ALL. By use of the 
CD5+/TdT + double immunofluorescence (IF) staining technique, it is possible to detect one 
CD5+/TdT + cell among 10,000 or even 100,000 normal cells, as has been established in a series 
of previous dilution experiments [3]. 
During follow-up of the mentioned T-ALL patient numerous peripheral blood (PB) and bone 
marrow (BM) samples were taken and analysed for the presence of residual T-ALL cells by use 
of the CD5/TdT double IF staining. For this purpose the mononuclear cells (MNC) were isolated 
from the obtained PB and BM samples by ficoll density centrifugation (Ficoll-Paque; density 
1.077 g/cm3). The MNC were incubated with the anti-CD5 monoclonal antibody (McAb) Leu-1 
(Becton Dickinson, Sunnyvale, Calif.) and subsequently with a tetramethylrhodamine-isothio- 
cyanate (TRITC) conjugated goat anti-mouse immunoglobulin (Ig) antiserum. Afterwards, at least 
two cytocentrifuge preparations per sample were made, each containing at least 25,000 cells. These 
preparations were fixed in methanol and subjected to an indirect staining for TdT by use of a goat 
anti-TdT antiserum (Supertechs, Bethesda, Md) and a fluorescein-isothiocyanate (FITC) conju- 
gated goat anti-rabbit Ig antiserum as a second step reagent. The cytocentrifuge preparations were 
evaluated on Zeiss fluorescence microscopes, equipped with phase-contrast facilities and filter 
combinations for the selective visualization of FITC and TRITC. The CD5+/TdT ÷ cells (i.e. 
T-ALL cells) present were quantified as percentages double positive cells per MNC, always by first 
determining the fraction of TdT + cells per MNC, followed by counting the TdT + ceils which were 
also positive for the second marker. For this purpose at least 1000 TdT + cells were evaluated each 
time. 
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For the mathematical nalysis of the data the percentages of T-ALL cells per MNC were 
recalculated to the absolute number of T-ALL cells per mm 3 of PB or BM. It should be remarked 
that within the MNC population after ficoU density centdfugation still myeloid cells are present 
(upto 15--20%). Those myeloid cells can easily be detected, since they strongly express the CDI5 
antigen, which can be marked by use of the McAb VIM-DS. Therefore, the percentage of T-ALL 
cells per MNC (= Z) was first corrected for the presence of CDI 5 + cells per MNC (= X) to obtain 
the percentage of T-ALL cells per "true" MNC (i.e. MNC not polluted with myeloid cells). The 
percentage of myeloid cells per total leukocytes (= Y) was obtained from differential counts of the 
PB or BM. This percentage was used to correct he percentage of T-ALL cells per "true" MNC 
to the percentage of T-ALL cells per total leukocyte population [= Z.  (100-  X) -~. (100-  I0]. 
Subsequently, the total number of T-ALL cells per mm 3 was calculated by use of the BM cell count 
or the white blood cell count (WBC) per mm 3 (= C). 
These calculations can be summarized in the following formula: 
# T-ALL = Z. 10-2" (100  --  X )  -~ .(100 - Y).C, (1) 
where # T-ALL denotes the total number of T-ALL cells per mm 3 PB or BM. 
Mathematical nalysis 
A very general growth equation describing the time course of a cell population of size C(t) at 
time t is given by: 
C(t + At) = C(t) + At. tiC~tit. (2) 
In the present case the time increment At was chosen 0.01 d in a series of computer simulations. 
The growth rate dC/dt was derived from the experimental data, bearing in mind some already 
available knowledge about tumor growth [5], both under unperturbed circumstances and under 
influence of chemotherapy, which will be briefly elucidated below. 
Unperturbed growth. The unperturbed development of a population of leukemia cells is often 
characterized by exponential growth, i.e. the population doubling time, /'2, is constant and in a 
log-linear plot a straight line is seen. In particular this is commonly true in the early stage of the 
disease. At a later stage T2 may increase more and more with time, and the population evolves to 
a steady state plateau phase (constant size). For instance, in the Brown Norway rat acute 
myelocytic leukemia--whose characteristics correspond closely to the human acute myeloid 
leukemia [6]--such behaviour is observed. After an exponential growth phase/'2 starts increasing 
exponentially, which can be described with a Gompertz function [7]. 
In general the increase of the population size per unit time can be related to the current 
population size as follows: 
dC/dt = GF. C(t), (3) 
where GF = In 2/1"2 is constant in the exponential growth phase, and for Gompertzian growth 
GF = A .ln(C,~/C), thus depends on the current and the maximum population size (plateau 
phase), as well as on a retardation constant, A. 
This growth fraction GF can be regarded as that part of the population that doubles its size 
during time interval dt. It is related to biological variables like the generation time of the cell line 
(time from birth of a cell until cell division), the ratio of resting and actively proliferating cells, 
the loss of cells from the population, and environmental factors. 
Influence of chemotherapy. Based on experiments measuring the increased lifespan of tumor 
bearing laboratory animals due to chemotherapy the "log cell kill" hypothesis [8] states that a given 
dose of a given cytostatic agent always kills a constant fraction of cells, rather than a constant 
absolute number. After this instantaneous reduction in cell number the drug effect has disappeared 
and the surviving population regrowths in a way similar to the unperturbed growth. This hypothesis 
has been widely accepted for describing chemotherapeutic impact on the size of a cell population 
[9]. Thus, a drug dose is said to have an effect of B log cell kill if the population sizes just before 
(time t-)  and just after (time t +) the administration are related by: 
C(t +) = C(t -). 10 -B. (4) 
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If a series of equally spaced constant drug doses are administered to a population in exponential 
growth, and assuming that the doubling time during regrowth will be identical to that of the 
original unperturbed population, then, on a log-linear plot, the population's time-history will be 
a regular saw-tooth shaped curve. Because ach sequential dose will kill a constant fraction of cells 
this curve will progress along a straight line, whose slope (either up- or downward) depends on 
the log cell kill factor per dose and on the T 2. 
The time-history of the average population s ize--C(t)= {C( t - )+ C(t+)}/2--can then be 
described with the equation: 
dC/dt  = GF. {l - K. L(t)}. C(t), (5) 
where--as in Norton and Simon [10]--K is a scaling constant and L( t )  a function that describes 
the therapy level, in this case having a constant value as well. Substitution of equation (5) into 
equation (2) will yield a "smoothed" time-history of the population's size (not showing every single 
saw-tooth) which can be used even when--like in the present case--the drug doses are not evenly 
spaced, nor constant with respect to the log cell kill factor. If K. L (t) is less than one the population 
will increase (exponentially) in size despite the therapy, if it is greater than one the malignant 
population will become (exponentially) smaller. The latter situation will correspond with RIT, the 
former situation may exist during less severe CMT which eventually results in a relapse as soon 
as the population size exceeds a minimum value (clinical detection level) again (see Fig. 1). Of 
course, deviations from the exponential curves may occur if, for any reason e.g. spontaneous 
mutation [l l], cell kinetic changes [12], or--in this case with one PB compartment not very 
likely--pharmacological hanges [13], drug insensitive (sub)populations start to develop. The 
constant log cell kill hypothesis valid for drug sensitive cells only; gradually arising drug resistant 
cells will lower the achieved log cell kill factor more and more. 
In the present case no tendency towards Gompertzian growth was observed. Inspection of the 
datapoints suggested exponential regrowth under CMT, identically for all three cycles, and, at least 
initially, an exponential decrease in population size during RIT. This decrease seems to continue 
at a lower rate later on (Fig. 2). 
For the reconstruction f the (smoothed) time-history of the population by computer simulation 
the influence of chemotherapy was split into two parts: 
(1) as there were, at a first glance, no signs in the observed atapoints that would 
indicate the formation of therapy resistant subpopulations, a constant influence 
corresponding with CMT is assumed for the total treatment interval. K.L ( t )  in 
equation (5) is smaller than one, and GF. { 1 - K .  L ( t )}  is a positive constant, GFr. 
REMISSION INDUCTION 
THERAPY MAINTENANCE THERAPY 
time 
Fig. 1. Qualitative influence of(high and low intensity) chemotherapy on the size of a cell population under 
(a) the "log cell kill" hypothesis ( ) or (b) development of herapy resistance (---). The thin solid lines 
show a "smoothed" time-history (connecting datapoints just before ach new drug administration). 
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(2) the initial high intensity chemotherapy corresponding with RIT--from which the 
already accounted for influence due to modeling CMT as in (1) is subtracted--is 
modelled to have an ever decaying influence according to: 
K.L ( t )  = H0. exp(-R .t), 
where R is a measure of the rate of decay from the initial therapy level H0. For, 
at first sight, therapy resistance formation like phenomena seem to play a possible 
role here. 
(6) 
Thus, the resulting rowth equation can be written as: 
C(t + At) = C(t) + GF,. {1 - Ho.exp(-R. t),}. At. (7) 
The value of GFr was estimated from a log-linear regression analysis of the experimental 
PB datapoints for CMT. The values of H0 and R were estimated for each of the three treatment 
cycles by fitting the simulated curve of equation (7) to the observed datapoints, using a 
standard routine for least squares fitting to a non-linear function with parabolic expansion of 
chi-squarc [14]. 
RESULTS AND DISCUSSION 
Figure 2 shows the datapoints observed after immunological marker analysis. It should be noted 
that for a number of datapoints he degree of contamination f the MNC population with myeloid 
cells [percentage Xin equation (1)] could not be determined. An average value for Xwas substituted 
then, yielding datapoints that are slightly less certain. The patterns for PB and BM data arc quite 
similar, except perhaps at the end of the time interval (day 400). The PB data were used for further 
mathematical analysis. 
Log-linear regression analysis in the regrowth phases, when influences of RIT has virtually 
vanished and only CMT influence remains, revealed that the population doubling time remained 
approximately constant, /'2 = 6.7, 5.8 and 7.7 d, respectively, for the three cons~utive cycles. 
(N.B. in the first cycle the datapoints in between the additional prednisone treatments were 
taken.) These differences are not significant and after pooling of the data the mean doubling 
time amounted to 6.5 d (correlation coefficient r = 0.991), which corresponds with a constant 
GFr = ln2/T~ = 0.106 d -1 (Fig. 3). 
This indicates that the growth kinetic properties of the regrowing population will not have 
changed uring the courses of treatment, and that the population remains in exponential growth 
phase even under CMT, without any evidence that therapy resistant cells are being formed here. 
In the same way an estimate of the half-time was obtained in the declining phase of the growth 
curve (Fig. 3). 
With the thus derived estimate for GF, the remaining parameters describing the therapy level, 
H0 and R in equation (7), were found for each treatment cycle by fitting the equation (7) to the 
corresponding datapoints, tarting from 2 x l0 s T-ALL cells/ram 3 blood on day zero. The resulting 
values are listed in Table 1. The resulting fitted curves representing the time-history of the T-ALL 
population in PB are shown in Fig. 4. 
As can be seen in Fig. 4 the fitted curves predict a minimum of about 0.1 T-ALL cell per ram 3 
of peripheral blood in the range of day 230-280. The corresponding datapoints--indicated in 
Fig. 4, although not been used for curve fitting purposes--have b en arbitrarily set to 0.01, but 
in this range the actually observed numbers amount o zero. These observations do not contradict 
the model output. A typical sample size for the immunological marker analysis in this region is 
10 ml blood, containing 3000 cells per mm 3. According to the model the frequency of the leukemic 
cells then is 0.1/3000 = 3.3 x 10 -5. This value is within the margin of the stated sensitivity of this 
detection method, i.e. 1 leukemic ell in 104-105 normal cells will be detectable [3]. Furthermore, 
a simple calculation using Poisson statistics reveals that, if the chance that a cell is leukemic equals 
3.3 x 10 -s, the probabilities of finding zero and of finding one of such cells in a sample of 30,000 
(10 ml blood) will be equally large, namely 37%. 
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Fig. 2. Experimental datapoints showing population size at 
various times; open symbols are less certain points (see text); 
start and duration of remission induction therapy is shown 
(thick arrows); thin arrows indicate additional treatment. 
BM--bone marrow; PB--peripheral blood. 
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Fig. 4. Computer simulation of the time-history of the population after the start of each treatment 
(4F--remission i duction therapy or ~--additional prednisone treatment), i.e. least squares fit of equation 
(7) to the datapoints (open symbols are less certain observations, see text); parameters in Table I. 
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That the effectivity of the RIT part of the therapy is reduced in every new treatment cycle can 
be deduced from (Table 1): 
(A) the initial therapy level H0 decreases with the cycle number; the rate of decay R 
does not change very much. The half-time of this decay amounts to some 23 d, 
which is nearly as long as the duration ofa RIT protocol. N.B., for the prednisone 
treatments just the reverse is observed, i.e. H0 increases to double the value and 
so does R. However, this may be an artifact due to too few datapoints in these 
regions. For instance, for the first prednisone treatment an almost equally good 
fit could be obtained by assuming H0 = 335.6 and R = 20.86, i.e. a very steep 
decay from a very high initial level. So, to evaluate the most appropriate 
parameter values more datapoints are necessary; 
(B) the area under the L(t) curve, which may serve as a measure of the therapy 
efficiency and can be calculated by integration of equation (6) from time zero until 
infinity (yielding Ho/T), goes down with the cycle number. N.B., for the 
prednisone cases the area under the curve goes down a little as well; 
(C) by looking at the ratio of the population size at the start of each RIT and the 
minimum population size achieved in that cycle, decreasing overall log cell kill 
values can be derived; 
(D) the relative growth rate just after the start of treatment shows ever decreasing 
values, showing that the decline of the population size is less and less steep. Just 
before treatment he relative growth rate always shows an approximately 
constant value, indicating that the state of the growing population is the same 
each time. Prednisone treatments again show a deviant behaviour. 
CONCLUSION 
From this pilot study it can be deduced that: 
(i) assuming a constant influence of low intensity maintenance therapy the otherwise 
"unperturbed" population in this T-ALL patient grows exponentially with a 
mean doubling time of 6.5 d, no matter the preceeding treatment history; 
(ii) intensive remission induction therapy can be modelled with an exponentially 
decaying therapy level L(t) which, in a series of equal treatments, depends on 
the sequence number. As it increases the efficiency of the remission induction 
therapy decreases, which is apparent from the facts that (1) L(t) shows a less 
steep decay from a lower initial value; (2) the area under the curve decreases and 
(3) the induced overall og cell kill decreases. This indicates the development of
therapy resistance. 
Finally, it can be said that these results indicate that mathematical nalysis of data obtained by 
a sensitive method for the detection of low numbers of malignant cells yields valuable information 
about the growth characteristics of the cell population, as well as about its sensitivity to 
chemotherapy. The mathematical nalysis suggests further experimental investigations on the 
Table 1. Results of curve fitting 
GF,= 0.106d -I T2 - 6.52d 
Therapy R + sd AUC (dC/dt)/C 
(d) H 0 + sd (d-') (d) LCK (d-t)t 
0:~ 6.972 0.264 0.0304 0.0013 229.34 6 - -  -0.63 
121 1.503 0.005 0.1137 0.0003 13.22 - -  0.09 -0.05 
177 2.856 0.004 0.2256 0.0004 12.66 - -  0.99 -0.19 
198:~ 5.086 0.008 0.0277 <0.0001 183.61 4 0.10 -0.43 
3655 2.386 <0.001 0.0207 <0.0001 115.27 ! 0.10 -0.15 
tJust before and after start of therapy. 
:[:Remission induction therapy. 
GF,, T2--growth fraction and doubling time in maintenance therapy phase; H e, R--initial therapy level 
and decay rate; AUC--area under therapy level curve; LCK--Iog cell kill; (dC/dt)/C--relative 
growth rate. 
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emergence of a drug resistant subpopulat ion. It would be interesting to make in vitro cultures of 
T -ALL  cells taken from the populat ion at various instants in the course of the treatments and see 
whether (A) the unperturbed growth kinetics (doubling time) indeed remain the same, and (B) the 
response to administrat ion of the various drugs changes. Another approach would be to look for 
a possible amplif ication of mult i -drug resistance (MDR)  genes increasing with time. This would 
be expressed as an ever increasing amount  of MDR gene products, to be detected by immunocyto-  
chemical assays. For instance, Ma et al. [15] in this way showed a correlation between the amount  
of P-170 plasma membrane glycoproteins and the presence of MDR cells in two cases of acute 
non- lymphoblast ic leukemia. 
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